In addition to identifying NAbs targeting SARS-CoV-2's S protein, a pilot trial to use recombinant soluble human ACE2 in COVID-19 patients has been initiated (clinicaltrial.gov #NCT04287686). The gene discussed is PROS1; the disease is COVID-19.